A Phase 1, Open-label, Single-dose, Randomized, Two-period, Crossover Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adult Participants
Latest Information Update: 08 Nov 2023
At a glance
- Drugs Brincidofovir (Primary)
- Indications Smallpox
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Acronyms BCV-001
- Sponsors Emergent BioSolutions
Most Recent Events
- 01 Nov 2023 Status changed from recruiting to completed.
- 10 Jul 2023 New trial record